Multiple Myeloma Cancer Antibodies

Multiple Myeloma Cancer Antibodies

Myeloma cancers are the fourteenth most diagnosed cancer in the United States, with about 1.6% of new cancer cases classified as myeloma and contributing toward 1.9% of cancer deaths yearly. As of 2012, there were approximately 90,000 people living with myeloma in the United States. Those diagnosed with myeloma have a 5 year survival rate of only 46.6%. Over the last 10 years, the rate of new kidney cancer cases has risen 0.8% per year, while the death rate has fallen 0.9% per year. Biocare Medical is proud to offer key myeloma antibodies that may aid in the identification of their respective proteins by IHC in FFPE tissues.

SEER Cancer Statistics Factsheets: Myeloma. National Cancer Institute. Bethesda, MD,

Biocare Clone